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Abstract
Background: Performance of the BED assay in estimating HIV-1 incidence has previously been evaluated by using
longitudinal specimens from persons with incident HIV infections, but questions remain about its accuracy. We sought to
assess its performance in three longitudinal cohorts from Thailand where HIV-1 CRF01_AE and subtype B9 dominate the
epidemic.
Design: BED testing was conducted in two longitudinal cohorts with only incident infections (a military conscript cohort and
an injection drug user cohort) and in one longitudinal cohort (an HIV-1 vaccine efficacy trial cohort) that also included long-
term infections.
Methods: Incidence estimates were generated conventionally (based on the number of annual serocoversions) and by
using BED test results in the three cohorts. Adjusted incidence was calculated where appropriate.
Results: For each longitudinal cohort the BED incidence estimates and the conventional incidence estimates were similar
when only newly infected persons were tested, whether infected with CRF01_AE or subtype B9. When the analysis included
persons with long-term infections (to mimic a true cross-sectional cohort), BED incidence estimates were higher, although
not significantly, than the conventional incidence estimates. After adjustment, the BED incidence estimates were closer to
the conventional incidence estimates. When the conventional incidence varied over time, as in the early phase of the
injection drug user cohort, the difference between the two estimates increased, but not significantly.
Conclusions: Evaluation of the performance of incidence assays requires the inclusion of a substantial number of cohort-
derived specimens from individuals with long-term HIV infection and, ideally, the use of cohorts in which incidence remained
stable. Appropriate adjustments of the BED incidence estimates generate estimates similar to those generated conventionally.
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Introduction
The development of serologic assays to detect recent HIV-1
infection and to estimate HIV-1 incidence has generated
widespread interest in applying this approach to monitor the
HIV epidemic [1–4] and to identify appropriate populations for
efficacy trials. Although incidence has previously been estimated
from serial prevalence data and survival assumptions, back-
calculation from AIDS case reporting, self-reported serologic
history, or passive anonymous/linked surveys [5–7,9–11], the
accurate estimation of incidence has traditionally relied on
prospective HIV-1 testing and longitudinal follow-up of people
at risk [12–15]. However, these cohort studies are time consuming,
logistically difficult, expensive, and subject to biases related to
enrollment, behavior change, preventive measures, interventions,
loss to follow-up and other study effects. Laboratory assays to
determine incidence by using cross-sectional sampling could
obviate some of these problems.
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In the last decade, a number of assays have been described for
the detection of recent HIV-1 infections (reviewed in [3,4]). These
assays rely on features of early HIV-1 infection such as the
presence of virus before antibody seroconversion (HIV-1 RNA or
HIV-1 p24 antigenemia) or the characteristics of antibody titer,
proportion, specificity, isotype, or avidity that differ between early
and established infection. These assays define the duration of a
transient state related to the evolving response to HIV-1 infection.
The prevalence of this transient state in the at-risk population
divided by its duration is an estimate of incidence (new infections
per person per unit of time).
Before application to population surveys, the assay-defined
demarcation of recent from longer-term infection and the mean
period of time that the recent state persists in the normal evolution
of infection (the recency period of the assay) are determined using
specimens collected serially from recently infected people (sero-
conversion panels). Assay parameters developed and defined in
this way are predicted to apply to cross-sectional population
samples, although there may be subtle or unforeseen reasons why
they do not. For instance, the recency period for a given assay may
differ by HIV-1 subtype [16], requiring selection of the
appropriate recency period for populations in areas such as
Thailand, where more than one subtype predominates. Another
factor is the prevalence of false-recent infections. The BED
estimates can be adjusted to account for the proportion of false-
recent infections [17–19].
In this study, we evaluated an assay for recent infection, the
BED capture enzyme immunoassay (BED-CEIA, abbreviated as
BED in this manuscript) [20,21] . The BED assay measures the
proportion of IgG that is directed against the immunodominant
region of HIV-1 gp41. The target antigen is a branched peptide
containing consensus gp41 sequences from multiple HIV-1
subtypes [21]. Responses to this peptide rise during the first 2
years following seroconversion, as measured by the BED [16,21].
The BED assay was applied to specimens from three cohort studies
in Thailand, where CRF01_AE and subtype B9 account for the
majority of HIV-1 infections. The cohort studies enrolled
seronegative participants in three cohorts at different times and
places, with different risks, with conventionally estimated inci-
dences varying from 1.2 to 7.0 per 100 person-years (PY) and with
varying durations of follow-up. In one cohort, the proportion of
persons with long-term infections increased over 3 years, allowing
evaluation of the impact of long-term infections. The convention-
ally estimated incidences were compared to the BED-estimated
incidences before and after adjustment.
Materials and Methods
Cohorts
The Royal Thai Army conscripts study. This study was
conducted in Northern Thailand during 1991–1993 [12,22]. HIV-
1 seronegative male conscripts (n = 1115) entering the military
were screened for HIV-1 seroconversion at 5, 17, and 23 months.
Adherence to follow-up was excellent, and all seropositive
specimens were available for BED testing.
The Bangkok Metropolitan Administration (BMA)
study. This study was conducted in 15 BMA narcotic
treatment clinics during 1995–1998 [13,23]. Injection drug users
(IDUs) (n = 1209) without serologic evidence of HIV-1 infection
were enrolled from mid 1995 through 1996 and tested for HIV
approximately every 4 months for .2 years. Cross-sectional
analyses were performed on specimens collected at 8, 16, and 24
months after enrollment and at the end of each calendar year.
Specimens from 91 of 120 seroconverters were available for
testing. Molecular subtyping of HIV-1 was performed as described
elsewhere [24].
The AIDSVAX B/E/phase 3 HIV-1 vaccine trial
(Vax003). This was a randomized, double-blind, placebo-
controlled, efficacy trial of AIDSVAX B/E, a bivalent
recombinant gp120 vaccine (VaxGen, Inc., Brisbane, California)
[25] known not to induce immune responses to the region of gp41
used in the BED assay [21,26]. The trial was conducted in 17
BMA narcotic treatment clinics from March 1999–June 2003.
HIV-1–seronegative participants (n = 2545) were tested for
serologic evidence of HIV-1 infection every 6 months for 36
months (90% completed follow-up). Seroconverters were retested
within a few weeks of their first seropositive test and followed up
every 4 months thereafter. Banked specimens collected between
May 1 and August 31 of years 2000, 2001, and 2002 represented
the cross-sectional populations. Specimens were available for most
(193) seroconverters. No one contributed more than one specimen
for each collection period.
Ethical review. All participants gave written informed
consent for HIV testing. The studies were approved by ethical
committees of the Centers for Disease Control and Prevention
(CDC), the Ministry of Public Health, and the BMA. The CDC
IRB numbers were 1825, 2076, 2255. The details of each study
can be provided by J. McNicholl or P. Wasinrapee, including
consent forms for HIV testing.
BED capture enzyme immunoassay. The BED was
performed on HIV-1–seropositive specimens as previously
described [21]. An 0.8 cutoff value for the normalized optical
density (ODn) was used to demarcate ‘‘recent’’ from ‘‘established’’
infection status. Using BED data from 190 seroconversion panels
from Thailand [16], we determined the mean period from initial
seroconversion to an ODn of 0.8 (the recency period) as 152 days.
Comparison of conventionally and BED-estimated
incidences. Conventionally, incidence in cohorts is estimated
by the number of new infections per 100 PY of observation. These
data were available for the three cohorts. To estimate incidence by
the BED assay, seropositive specimens from these studies were
tested for recent infection. The number of seropositive specimens
that were classified as ‘‘recent’’ by the BED assay (Ninc) divided by
the recency period in days (w) gave the number of incident
infections per day. This number times the number of days in one
year (365) gave the annualized BED-estimated number of incident
infections: ([Ninc/w]6365). The relevant comparison for this study
is the conventionally estimated number of incident infections
during a given period versus the BED-estimated number of
incident infections for the same period (i.e. the numerators in the
incidence formulae). The BED cross-sectional estimation
necessarily uses an ‘‘at risk’’ formula: BED-estimated recent
infections in one year per number of persons at risk. The number
at risk is the number of seronegative persons plus the estimated
number of recently infected persons in the screened population.
Since the statistical treatment and results are the same with either
denominator, we arbitrarily present only the PY-derived incidence
values in the tables. Binomial 95% confidence intervals (CIs) were
calculated for conventionally and BED-estimated incidences by
using a calculation worksheet provided by A.Welte [17]. Differences
between conventionally and BED-estimated incidences were
considered insignificant (p.0.05) if the 95% confidence intervals
of the estimates overlapped.
When specimens from all the seroconverters were not available
for testing, the BED estimate was extrapolated by the factor (No.
of seroconverters/No. of seroconverter specimens available for
testing). This assumes that the proportion of specimens that test
positive for recent infection is the same for persons with available
BED Assay in Thailand
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specimens and for those whose specimens were missing. The
calculation of confidence and the statistical comparisons are based
on data from tested specimens, not from extrapolated data. In
analyses of long-term specimens (defined as specimens from
seroconverters infected in prior years), data were adjusted for
misclassification by using a recently described formula [17].
Results
In the Royal Thai Army conscripts study (Table 1), men were
enrolled at the same time and followed up regularly. There were
14 seroconverters in this study. There was general agreement
between the conventionally estimated and BED-estimated inci-
dence for all periods. The overall difference in BED-estimated
(1.43 per 100 PY) and conventionally estimated (1.19 per 100 PY)
incidence was 0.24 per 100 PY, which is not significant.
In the BMA study (Table 1), the annualized conventionally
estimated incidence was 6.96 per 100 PY, and the BED-estimated
incidence was 5.49 per 100 PY. This overall difference of 1.47 per
100 PY was not significant. With the exception of the analysis for the
first 8 months of enrollment, the two incidence estimates were not
significantly different for the individual periods. For the first 8 months
of enrollment, the BED-estimated incidence (5.22/100 PY) was lower
than the conventionally estimated incidence (7.91/100 PY). Con-
ventionally estimated incidence was not stable during the first 8
months. More seroconversions occurred during the first 4 months of
enrollment than during the second 4 months, and the annual
conventionally estimated incidences, calculated separately for the first
and second 4-month periods, were 9.49/100 PY and 5.00/100 PY,
respectively. The BED estimate is determined by the number of
seroconverters who are within the recency period at the time of
specimen collection. Thus, the BED incidence estimate, based on
specimens collected at the end of the 8-month interval, corresponds
more closely to the conventional estimate for the second 4 months
than it does to the conventional estimate for the first 4 months or the
first 8 months. We could not analyze consecutive 4-month periods
because the sample frame overlapped with the recency period,
leading to possible truncation of the BED estimate.
In the BMA study, we compared incidence measures separately
for infection with HIV-1 CRF01_AE and subtype B9, the
predominant subtypes in Thailand. For CRF01_AE, the conven-
tionally estimated incidence was 5.37 per 100 PY (95% CI, 4.26–
6.49), and the BED estimate was 3.91 per 100 PY (95% CI, 1.20–
6.62). For subtype B9, the respective measures were 1.43 (95% CI,
0.88–1.98) and 1.43 (95% CI, 0.00–3.02).
In the Vax003 trial (Table 2) we were able to examine the effect
of long-term infections. There were 203 seroconverters. Overall,
BED-estimated (3.73 per 100 P-Y) and conventionally estimated
incidences (3. 71 per 100 P-Y) did not differ significantly.
Comparison of all the annualized incidence results in the column
labeled ‘‘conventional’’ incidence and the first column (without
LT) in the section labeled ‘‘BED’’ shows that the data are similar.
These analyses were confined to specimens from participants who
had seroconverted and been tested in the indicated year. As the
study progressed, specimens collected in the designated year from
participants who had seroconverted in previous years became
available. As data from these long-term participants accumulated,
there was inflation of the BED estimate (compare BED column
‘‘without LT’’ with column ‘‘with LT’’). For example, when long-
term specimens were added in the year 2002, the BED estimate
increased from 4.38 to 6.03. When these data were adjusted for
misclassification, by using a recently described formula [17], the
adjusted BED estimates were lower. The overall adjusted BED
estimate was 3.75 per 100 PY, much closer to the conventionally
estimated incidence of 3.71 per 100 PY (see Table 2, column
labeled ‘‘with LT ’’ compared to column labeled ‘‘ with LT
(adjusted)’’ and to column labeled ‘‘conventional’’). This compar-
ison indicates the importance of adjusting the BED estimate when
the analysis includes persons with long-term infections, as would
be typical in most cross-sectional surveys.
Discussion
In these studies, BED testing was performed on specimens from
the same cohorts where incidence was conventionally estimated.
The use of the same specimens is an advantage over study designs
where BED-estimated incidence is determined on specimens that
are related to, but separate from, those of the referent cohort. For
instance, the true incidence in the pre-enrollment screening for a
cohort study or in a separate cross-section of the same population
Table 1. Comparison of conventionally and BED-estimated incidence in two cohorts.
Time Period PY No. at risk Estimated No. of incident infections Annualized incidence/100 PY
Conventional BED Conventional (CI) BED (CI)
Thailand military conscript cohort
Months
5 324 867 2 2.0 0.62 (0.00–1.48) 1.49 (0.00–3.57)
17 660 662 9 9.5 1.38 (0.47–2.29) 1.48 (0.02–2.93)
23 207 472 3 1.2 1.47 (0.00–3.15) 1.18 (0.00–3.49)
Subtotal 1191 14 12.7 1.19 (0.56–1.82) 1.43(0.36–2.49)
BMA injection drug user cohort
Months
8 709 942 52 34 7.91 (5.68–10.15) 5.22 (4.65–9.87)
16 620 805 38 34 6.53 (4.39–8.67) 5.85 (0.48–11.22)
24 515 668 30 28 6.19 (3.90–8.47) 5.77 (0.00–14.43)
Subtotal 1844 120 96 6.96 (5.67–8.25) 5.49 (2.22–8.76)
PY, person-years; CI, 95% confidence interval; BMA, Bangkok Metropolitan authority.
doi:10.1371/journal.pone.0014748.t001
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may not be equivalent to the incidence measured in the related
cohort because of selection bias, recruitment bias, or both. The
design also allows evaluation of the window and allows subanalysis
of features that affect assay performance. We were alerted to two
such features in this study: the effect of unstable incidence and the
influence of specimens from long-term infected participants.
Incidence estimates from cohorts and from cross-sectional
analysis differ fundamentally. Cohort data are collected during
prescribed periods, whereas the cross-sectional method produces
an estimate at a given point in time. Cohort data measure the
number of seroconversions that occur during a given period of
follow-up and are frequently used as the criterion standard. The
cross-sectional analysis is dependent on the number of serocon-
verters who are within the recency period (in this instance, 152
days) at the time of specimen collection. The incidence rate that is
actually measured is the number of recent infections per 152 days.
Extrapolation of this value to a longer period (e.g., 365 days for an
annualized estimate) is based on the assumption that the rate
remains the same. If the rate is not constant, the BED estimate,
extrapolated to a period longer than the recency period, will be in
error. An example of this occurred during the first 8 months of
follow-up in the BMA study, when more seroconversions during
the early part of the period biased the BED estimate, resulting in
an underestimate of the conventionally estimated incidence
(Table 1). This observation highlights the importance of
understanding the relationship of recency period to the sampling
period of a cohort study and how fluctuations in incidence during
the sampling frame may bias BED results.
The recency period used for calculating BED incidence in this
study was 152 days. This period was based on analysis of
seroconversion panels from 190 seroconverters representing
subtypes B9 and CRF01_AE [16]. The recency period that would
have given precise agreement between conventionally and BED-
estimated incidences can be calculated by entering the conven-
tionally estimated incidence into the BED incidence formula and
solving for the recency period. This calculation would result in a
recency period of 140 days (range, 130–153 days). Thus, the
recency period used and the recency period that would have given
perfect concordance in the conventionally estimated and BED-
estimated incidences are similar.
In the Vax003 cohort, the effect of long-term infections was
observed. The BED estimate was based on analysis of specimens
collected at the end of each year from those who seroconverted in
that year (Table 2). As the study progressed, specimens collected in
the designated year from participants who had seroconverted in
previous years (longer-term infected persons) became available.
These specimens should, in theory, be classified as long-term
infections in the BED assay, but approximately 5% of these
specimens register false-recent BED results [18,19]. As more and
more specimens from participants infected for longer periods of
time accumulated, the prevalence of seropositive persons in the
cross-sectional samples rose. Consequently, the small portion of
false-recent BED results inflated the BED-estimated incidence
(Table 2). This analysis is most relevant to the context in which the
BED assay is currently widely used: cross-sectional populations
with a predominance of longer-term infected people.
The inflation of the incidence estimate related to false-recent
results for long-term infected subjects can be substantial, rises with
increased prevalence in the test population, and has been noted
before [17–19,21,27–29]. The need for further studies in this
regard has been pointed out by many [18–20,27,30,31]. There are
several potential ways of mitigating these effects. To some extent,
persons who are known to have long-standing infection can be
classified as having long-term infection as part of case-based
surveillance [31]. Participants who self-report or otherwise are
known to be long-term HIV-1–seropositive [6,8], patients with
AIDS [11,15], or patients receiving antiretroviral therapy [31,32]
are unlikely to be recently infected and likely to register recent by
the assay. This history may be available or can be included in the
design of the cross-sectional study and can complement the testing
classification. A more stringent testing algorithm could be used,
one that requires confirmation of BED-recent specimens with a
second test for recent infection and the addition of testing for the
presence of antiretroviral drugs in specimens that are BED-recent.
The use of posttest mathematical adjustments that correct for
misclassification have been proposed by several investigators [17–
19,21]. These adjustments rely on an accurate estimate of the
anticipated false-recent rate in long-term infected participants [17–
19,21]. If the false-recent rate is accurate and relevant to the
population being screened, the correction works quite well, as
shown in the analysis of the VAX003 data (Table 2). However,
relevant data may not be available, or special screening over time
in the test population may be required to generate the data
[30,31].
Our results suggest that the BED estimate of incidence, when
determined on specimens from prospective cohort studies of
initially HIV-1–seronegative persons, is comparable to the
independently estimated conventional incidence from the same
cohorts in Thailand, both for CRF01_AE and subtype B9.
The cohort design allows one to identify, model, and quantify
factors that perturb the estimate, two of which are noted here
(unstable incidence and the significant impact of long-term
prevalent specimens that may register false-recent in the assay).
The availability of tests for determining incidence has multiple
Table 2. Comparison of conventionally and BED-estimated incidence: effect of long term infections.
Test Year PY No. at risk Estimated No. of incident infections Annualized incidence/100 PY









2000 1551 2469 52 69 N/A 3.47 (2.51–4.43) 4.65 (2.64–6.66) N/A N/A
2001 2295 2347 71 58 70 3.19 (2.44–3.95) 2.64 (1.49–3.78) 3.17 (1.94–4.39) 2.59 (1.37–3.82)
2002 1836 1737 80 76 107 4.56 (3.53–5.58) 4.38 (2.47–6.28) 6.03 (4.00–8.06) 4.86 (2.84–6.88)
Total 5682 203 203 246 3.71 (3.19–4.22) 3.73 (2.78–4.68) 4.41 (3.43–5.39) 3.75 (2.77–4.73)
PY, person-years; CI, 95% confidence interval; LT, long-term infections. Adjustments were done as recommended by Welte et al. 2009 [reference 17].
doi:10.1371/journal.pone.0014748.t002
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potential advantages, not the least of which is that an incidence
testing program can easily be superimposed on surveillance
programs for HIV-1 prevalence. Several countries, Thailand
included, are supplementing national surveillance for HIV
infection by using BED-based incidence estimation while incor-
porating elements of case-based surveillance. A recent survey of
Thai military conscripts during 2005 and 2006 found a BED-
estimated incidence of 0.14 to 0.20% per year [33], a significant
decline compared with the estimate of 1.19 per 100 PY for 1991–
1993 (Table 1).
Many of the survey design, data collection, and sampling issues
related to prevalence estimates also apply to incidence estimates.
However, there will be issues, expected or otherwise, that are
unique to incidence testing and particularly to population-based
versus cohort-based settings. In implementing the BED method for
population-based surveillance, it will be important to be aware of
the biases, assumptions, and limitations of making incidence
estimates and to mitigate their impact by careful survey design,
testing, analytic adjustment, and extrapolation.
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